April 21, 2008 - InterMune, Inc. (Nasdaq: ITMN) announced that it will initiate an open-label roll-over study to evaluate the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF). The roll-over study will be open to patients who complete one of the two concurrent Phase 3 CAPACITY studies of pirfenidone in IPF. InterMune expects that the first patient will enter the roll-over study in August 2008... InterMune's Press Release -Blog Archive
-
▼
2008
(297)
-
▼
April
(50)
- NuRx Pharmaceuticals : Phase I Clinical Trial of F...
- Replidyne Discontinues Phase III Trial
- InterMune : Progress on Pirfenidone in Idiopathic ...
- MedImmune and Infinity : Preclinical Data Highlig...
- Diffusion Pharmaceuticals : patent no. 7,351,844 e...
- Micromet : Phase 1 Clinical Trial with MT110, the ...
- Sorin : approval to market heart-lung machine in J...
- Gene Express : licensing agreement with University...
- Genentech : "AVAiL" Phase III Study of Avastin Plu...
- Spectrum Pharmaceuticals : Preclinical Data Demons...
- Kosan : Phase 2 Trial of Epothilone KOS-1584 in No...
- Infinity Pharmaceuticals' Hedgehog Antagonist Dela...
- Oncolytics Biotech : Dose Escalation in Combinatio...
- Alfacell's ONCONASE : Potential as Radiation Sensi...
- Lilly's ALIMTA : European Approval for Histologica...
- Rosetta Genomics : Agreement With West Coast CLIA ...
- Pharmaxis : CF Trial in Children Returns Positive ...
- MedImmune : Asthma Program with Start of a Phase 2...
- Transave : Study Confirms Anti-Infective ARIKACE E...
- Antisoma and Novartis : phase III lung cancer tria...
- UCB : Phase II results for CDP791 in non-small cel...
- Dinamika : A New Asthma Treatment Introduced by Ru...
- SkyePharma : exclusive License Agreement with Kyor...
- eResearchTechnology, Inc. and nSpire Health, Inc. ...
- Alnylam : ALN-RSV01 in Adult Lung Transplant Pati...
- Critical Therapeutics : Phase I Clinical Trial of ...
- bioMerieux & University of Sunderland : Collaborat...
- TaiGen : Positive Data From the Phase II Study of ...
- Aeolus Pharmaceuticals : AEOL 10150 Protects Lungs...
- AVEO’s Novel Triple VEGF Receptor Inhibitor... Cli...
- Idera Pharmaceuticals : Preclinical Data of its To...
- Kamada : New Orphan Drug Designation by the FDA, f...
- Yale and Asuragen : a microRNA Can Reduce Lung Can...
- Aradigm : Trial of Lung Rx's Inhaled Treprostinil
- KaloBios : Phase 1/2 Trial of Humaneered Monoclona...
- Kamada : Phase III Clinical Trial with Intravenous...
- Cortex : Enrollment in Opiate Induced Respiratory ...
- Actelion and Nippon Shinyaku : pulmonary arterial ...
- Angeion : Medical Graphics Platinum Elite Series P...
- Ceragenix Pharmaceuticals : CeraShield(TM) Coated ...
- NIR Diagnostics : agreement with a European medic...
- Third Wave’s InPlex CF Molecular Test : FDA Clearance
- Celgene : Amrubicin Receives FDA Orphan Drug Desig...
- Lorus : initiation of IND-enabling toxicology stud...
- Poniard Pharmaceuticals : Commercial Manufacturing...
- OXiGENE : Phase II NSCLC Trial of ZYBRESTAT(TM) in...
- Discovery Labs and Chrysalis Technologies : about ...
- MediciNova : Phase II Clinical Trial of MN-221 in ...
- Vertex : Positive Results for VX-770, an Oral Inve...
- Philips : completion of Respironics acquisition
-
▼
April
(50)
Apr 28, 2008
InterMune : Progress on Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF)
April 21, 2008 - InterMune, Inc. (Nasdaq: ITMN) announced that it will initiate an open-label roll-over study to evaluate the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF). The roll-over study will be open to patients who complete one of the two concurrent Phase 3 CAPACITY studies of pirfenidone in IPF. InterMune expects that the first patient will enter the roll-over study in August 2008... InterMune's Press Release -
